Armistice Capital LLC lowered its stake in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 7.6% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,278,000 shares of the biotechnology company's stock after selling 758,000 shares during the quarter. Grifols comprises 1.0% of Armistice Capital LLC's portfolio, making the stock its 11th largest holding. Armistice Capital LLC owned approximately 1.35% of Grifols worth $65,967,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also recently bought and sold shares of the stock. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of Grifols by 4.6% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 46,078 shares of the biotechnology company's stock valued at $328,000 after purchasing an additional 2,026 shares in the last quarter. Sequoia Financial Advisors LLC increased its position in Grifols by 14.9% during the 1st quarter. Sequoia Financial Advisors LLC now owns 26,230 shares of the biotechnology company's stock worth $186,000 after buying an additional 3,399 shares during the period. Versant Capital Management Inc bought a new position in Grifols during the 1st quarter worth $28,000. Cerity Partners LLC grew its holdings in shares of Grifols by 22.8% during the 1st quarter. Cerity Partners LLC now owns 22,254 shares of the biotechnology company's stock worth $158,000 after purchasing an additional 4,129 shares in the last quarter. Finally, Cetera Investment Advisers grew its holdings in shares of Grifols by 16.1% during the 1st quarter. Cetera Investment Advisers now owns 35,254 shares of the biotechnology company's stock worth $251,000 after purchasing an additional 4,900 shares in the last quarter.
Grifols Trading Up 1.8%
Shares of GRFS traded up $0.18 during mid-day trading on Friday, hitting $10.08. 230,593 shares of the company's stock traded hands, compared to its average volume of 955,470. The firm has a market capitalization of $6.93 billion, a P/E ratio of 8.61, a PEG ratio of 0.34 and a beta of 0.64. The company has a quick ratio of 0.95, a current ratio of 2.64 and a debt-to-equity ratio of 1.20. The business's 50-day moving average price is $9.98 and its 200-day moving average price is $8.54. Grifols, S.A. has a 1 year low of $6.19 and a 1 year high of $11.14.
Grifols Dividend Announcement
The business also recently announced a special dividend, which was paid on Wednesday, August 20th. Investors of record on Tuesday, August 12th were paid a dividend of $0.1404 per share. The ex-dividend date of this dividend was Tuesday, August 12th. Grifols's dividend payout ratio (DPR) is presently 11.97%.
Analyst Upgrades and Downgrades
A number of analysts have recently commented on GRFS shares. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Grifols in a research note on Tuesday, August 5th. JPMorgan Chase & Co. lifted their target price on Grifols from $7.60 to $10.30 and gave the stock a "neutral" rating in a report on Tuesday, June 17th. Zacks Research raised Grifols to a "hold" rating in a research note on Friday, August 8th. Finally, Wall Street Zen raised Grifols from a "buy" rating to a "strong-buy" rating in a research report on Monday, July 7th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $10.30.
Check Out Our Latest Stock Analysis on GRFS
Grifols Profile
(
Free Report)
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
Featured Stories
Before you consider Grifols, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.
While Grifols currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
